All In Biotech

Drug Trial Radar · NCT00000914

A Study of the Effectiveness of Different Anti-HIV Treatments in HIV-Positive Individuals Who Have Been on a Protease Inhibitor-Containing Drug Regimen for at Least 16 Weeks

A Randomized Study of the Virologic Efficacy of Different Antiretroviral (AR) Treatment Strategies in HIV-Infected Individuals With Detectable Plasma HIV RNA Measurements After at Least 16 Weeks on Their Initial Protease Inhibitor-Containing AR Regimens

Last checked: Nov 19, 2026Latest source record: Oct 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

800

Actual

Start

Not stated

Primary completion

Not stated

Study completion Jun 2000

Sponsor

Sponsor type
NIH
First posted
Aug 31, 2001

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare different treatments for HIV infection to see which works best to lower HIV levels and to raise the number of CD4 cells (cells of the immune system that fight infection), in HIV-positive individuals who have been on a protease inhibitor-containing drug regimen for at least 16 weeks. Researchers have found that combination anti-HIV therapy (multiple drugs given together) can help prevent AIDS-related illnesses and help people with AIDS live longer. In this study, the anti-HIV drug efavirenz (EFV) will be tested with 1 or 2 other protease inhibitors (PIs) to see which combination works best to treat HIV infection. EFV has been shown to limit the amount of HIV virus produced by infected cells.

Conditions

  • HIV Infections

Interventions

  • Indinavir sulfateDrug

  • RitonavirDrug

  • Nelfinavir mesylateDrug

  • EfavirenzDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Community Consortium / UCSF

    San Francisco, California

  • Denver CPCRA / Denver Public Hlth

    Denver, Colorado

  • Washington Reg AIDS Prog / Dept of Infect Dis

    Washington D.C., District of Columbia

  • AIDS Research Consortium of Atlanta

    Atlanta, Georgia

  • AIDS Research Alliance - Chicago

    Chicago, Illinois

  • Louisiana Comm AIDS Rsch Prog / Tulane Univ Med

    New Orleans, Louisiana

  • Wayne State Univ - WSU/DMC / Univ Hlth Ctr

    Detroit, Michigan

  • Henry Ford Hosp

    Detroit, Michigan

  • Southern New Jersey AIDS Cln Trials / Dept of Med

    Camden, New Jersey

  • North Jersey Community Research Initiative

    Newark, New Jersey

  • Partners in Research / New Mexico

    Albuquerque, New Mexico

  • Harlem AIDS Treatment Grp / Harlem Hosp Ctr

    New York, New York

  • The Research and Education Group

    Portland, Oregon

  • Philadelphia FIGHT

    Philadelphia, Pennsylvania

  • Richmond AIDS Consortium / Div of Infect Diseases

    Richmond, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.